Interestingly, analysis of FGFR1–4 expression association with clinicopathological characteristics (Table 1) revealed that the FGFR4 mRNA expression was significantly higher in patients with lymph node metastasis (median: 0.02 vs. 0.01, p = 0.036; Figure 4), while FGFR1–3 expression levels were not significantly related to any of the clinicopathological features examined. This evidence concerns the gene FGFR4 and metastatic malignant neoplasm in the lymph nodes.